Cargando…
The Role of MicroRNAs as Predictors of Response to Tamoxifen Treatment in Breast Cancer Patients
Endocrine therapy is a key treatment strategy to control or eradicate hormone-responsive breast cancer. However, resistance to endocrine therapy leads to breast cancer relapse. The recent extension of adjuvant tamoxifen treatment up to 10 years actualizes the need for identifying biological markers...
Autores principales: | Egeland, Nina G., Lunde, Siri, Jonsdottir, Kristin, Lende, Tone H., Cronin-Fenton, Deirdre, Gilje, Bjørnar, Janssen, Emiel A. M., Søiland, Håvard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4632748/ https://www.ncbi.nlm.nih.gov/pubmed/26473850 http://dx.doi.org/10.3390/ijms161024243 |
Ejemplares similares
-
Metabolic consequences of perioperative oral carbohydrates in breast cancer patients — an explorative study
por: Lende, Tone Hoel, et al.
Publicado: (2019) -
Low Z‐4OHtam concentrations are associated with adverse clinical outcome among early stage premenopausal breast cancer patients treated with adjuvant tamoxifen
por: Helland, Thomas, et al.
Publicado: (2020) -
Digital Image Analysis of Ki-67 Stained Tissue Microarrays and Recurrence in Tamoxifen-Treated Breast Cancer Patients
por: Egeland, Nina Gran, et al.
Publicado: (2020) -
Effect of Genetic Variability in 20 Pharmacogenes on Concentrations of Tamoxifen and Its Metabolites
por: Chen, Yuanhuang, et al.
Publicado: (2021) -
Apolipoprotein D expression does not predict breast cancer recurrence among tamoxifen-treated patients
por: Klebaner, Daniella, et al.
Publicado: (2017)